Skip to main content
Premium Trial:

Request an Annual Quote

Gert Caspritz, Stephane Berghmans

Premium
EpiCept this week announced that Gert Caspritz has resigned from the company's board of directors, effective March 6.
 
Caspritz, a general partner of TVM Capital, has been a member of the board since 1999 and served as EpiCept's chairman from July 2002 until December 2004.
 

 
Znomics has named Stephane Berghmans as director of drug discovery, effective March 10, the company announced this week.
 
Berghmans was most recently head of safety pharmacology at Summit.

The Scan

Missed Early Cases

A retrospective analysis of blood samples suggests early SARS-CoV-2 infections may have been missed in the US, the New York Times reports.

Limited Journal Editor Diversity

A survey finds low diversity among scientific and medical journal editors, according to The Scientist.

How Much of a Threat?

Science writes that need for a provision aimed at shoring up genomic data security within a new US bill is being questioned.

PNAS Papers on Historic Helicobacter Spread, Brain Development, C. difficile RNAs

In PNAS this week: Helicobacter genetic diversity gives insight into human migrations, gene expression patterns of brain development, and more.